First test of new drug aimed at halting Cancer's devastating weight loss
NCT ID NCT07237464
Summary
This is the first-ever study in people of an experimental drug called GB18. It aims to see if the drug is safe and how it behaves in the body. The ultimate goal is to see if GB18 could one day help control the severe, debilitating weight loss (cachexia) that affects many cancer patients. The study will enroll 36 healthy adults who will receive a single injection of either GB18 or a placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER CACHEXIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.